Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 16;8:1334. doi: 10.3389/fimmu.2017.01334

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Liao, Xue, Zhao, Li, Liu, Chen, Brand, Zheng, Zhang, Zheng and Sun.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

iTreg treatment attenuates renal allograft rejection and injury and prolongs allograft survival. Renal allografts were obtained at 5 days post operation. (A) Survival time; (B) levels of antidonor-specific antibodies (IgG and IgM) before operation and at 5 days post kidney transplantation (KT5) by immunofluorescence and flow cytometry. Data are expressed as mean fluorescence intensity; (C) histological changes evaluated by the semiquantitative Banff scoring criteria: 0, absent; 1, mild; 2, moderate; and 3, prominent; (D) histologic evaluation of a rejected renal allograft posttransplant. The graft sections were stained with hematoxylin and eosin, periodic acid-Schiff (PAS), anti-C3d antibody, and anti-IgG antibody; (E) cell apoptosis posttransplant using TdT-mediated dUTP nick-end labeling (TUNEL) assay; (F) statistical analysis of graft injury (*p < 0.05, **p < 0.01).